BJ-1301

N/A

Report date: 2025/06/11 11:20:10

NME

Base Information

Drug NameBJ-1301

Drug Alias Nameangiogenesis inhibitors (Daewoo Pharmaceutical/ Yeungnam University)NADPH oxidase/receptor tyrosine kinase dual inhibitor (Daewoo Pharmaceutical/Yeungnam University)DWM-M01ABJ-1301DWM-M01S

ClassificationSmall molecules

Mechanisms of ActionNerve growth factor receptor Trk-A inhibitorsNADPH oxidase inhibitorsAnticancer protein kinase inhibitors +[4]

TargetsNerve growth factor receptor Trk-ANADPH oxidase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYeungnam University

China Registration ClassN/A

Develop Information

Active CompaniesYeungnam University

Inactive CompaniesDaewoong Pharmaceutical Co Ltd

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A